Index

Accounting, 41–42
  cost, 90–91
Administration, 7–8
  clinical, 7–8
  effective, 8
  inpatient, 87–88
    cost accounting, 90–91
    cost control, 90–91
    management, 89–90
    medical staff relationship, 91–92
    projection, 92–93
    public relations, 92
  research, 7
  teaching, 7
Adrenal androgenic hyperplasia, 83
Aldosterone-producing tumors, 84
Allergic diseases, 85–86
American Medical Association, 112, 113, 115
American Optical Company, 126
Anesthesia, 215
Angina pectoris, 82
Annual Report of H.M. Chief Inspector of Factories, 138
Anterior chamber, 174–177
  foreign body in, 148–149
  magnet extraction, 217–220
  nonmagnetic foreign body in, 238–246
Applanation tonometer, 15
Appointments
  scheduling of, 61–62
  solo practice, 13–14
Aronson, Mrs. Muriel Fox, 111
Artefacts, 169
Aspherical curves, 54
Aspiration, 249
Atherosclerosis, 81–83
Automation, 267–268
Auxiliary help, solo practice, 18–19

Barkley, Alben, 109–110
Billing for contact lenses, 56–58, 71–72
Birmingham and Midland Eye Hospital, 140, 141, 150
Bowman, Sir William, 118, 119
Bowman's membrane, 149
Bright light operative localization, 205–209
  glass fiber diaphanoscope, 206–207
  transillumination, 207–208
British Faculty of Ophthalmologists, 122
British Journal of Ophthalmology, 123
Bromley Eye Localiser, 185
Brown, E. V. L., 69

Campimeters, 124–125
Carl Byoir & Associates, 111
Carnegie, Dale, 115
Case history, 172
  importance of, 237–238
  legal aspects, 274
Celloidin, 168
Center of rotation as reference point, 183–184
Certified public accountants, 34, 42
Chalcosis, 164–166

Chemical injuries, 151–152
Chemically active inorganic materials, 239
Church affairs, 23–24
Ciliary body, 150
  foreign body in, 150
  nonmagnetic foreign body in, 245
Civic affairs, 23–24
Clarke, Clement, 123
Clinical administration, 7–8
Clinical research, 73–74
Clinical teaching, 47–51
  obligations, 48–50
  rewards, 50–51
Colleagues, referral to, 55–56
Community affairs, 23–24
Compensation, 272
Competition, 113–114
Conducting body, effect of, 197–198
Consultation, solo practice, 19–20
Contact lens
  billing for, 56–58, 71–72
  cost of, 60–61
  fitting, 103
    the process of, 63
  management, 53–74
    assistants, 69–70
    billing, 71–72
    clinical research, 73–74
    evolutionary problems, 53–55
    guarantee certifications, 65–66
    insurance, 64–65
    lost lens replacement, 66–67
    the receptionist, 70–71
    referral to a colleague, 55–56
    refraction room, 68–69
    routine procedure, 63–64
    scleral lens, 72–73
    scratched lens, 67
    soaking solutions, 67
    space, 67–68
    technicians, 56–61
    wetting solutions, 67
  patents, 53–55
Cornea, nonmagnetic foreign body in, 239–240
17-OH Corticoids, 83
Cost accounting, inpatient administration, 90–91
Cost control, inpatient administration, 90–91
Crisis in American Medicine, The, 108
Cross, A. J., 119
Crosswire, use of, 184–185
Cushing's syndrome, 83

Dennet's luminous ophthalmoscope, 118
11-Deoxycorticosterone, 83
11-Deoxycortisol, 83
Descemet's membrane, 149, 152
Diabetes, 84–85
Diaphanoscope, glass fiber, 206–207
Diathermy, 228
Diseases of the Eye (Swanzy and Werner), 127
Doctor Business, The, 108
Drug room, the, 78–79
Drugs in the office, 77–79

Economics, *see* Ophthalmic economics
Education, continuing, 44–45
Electromagnetism, 135
Electronic localization, 193–198
  apparatus, 194–195
  design considerations, 195–196
  effect of a conducting body, 197–198
  performance achieved, 196–197
Enzymatic zonulolysis, 245
Eosin, 168
Equipment, 104. *See also* names of equipment
  cost of, 62
  for refraction rooms, 23
Estimated Statistics on Blindness and Vision Problems, 138
Examination
  office, record of, 9–10
  procedures, 15–16

Eye, saving the, 162–163

Factories Acts, 265–266
Fibrosis, 160–161
Finance, 41–42
Fitting contact lens, 103
Foster chart, 122

Geometrical constructions, 189–191
Glass, 166
Glass fiber diaphanoscope, 206–207
Glaucoma, 261, 262
  secondary, 160
Globe
  determining diameter of, 183–184
  stabilizing of, 248
Glycol, 54
Goggles, 266–267
Gonioscopes, 126–127
Gonioscopy, 126–127
Goodyear Dental Vulcanite Company, 54–55
Graduate program, solo practice, 20–22
Granuloma, foreign body, 156–160
Graticule, 187–188
Gripping instruments, 247–248
Group practice, 25–38
  advantages of, 25–27
  certified public accountant, role of, 34
  design of office, 28–31
  dividing income, 37–38
  insurance agent, role of, 34–35
  lawyer, role of, 35–36
  leasing versus ownership of office, 32
  location of office, 27–28
  office personnel, 32–34
  reaching partnership status, 36–37
  selecting new associates, 36–37
  size of office, 28–31
Guarantee certificates for contact lens, 65–66

Guidelines for Physicians in Their Relations with News Media, 113
Gullstrand, Allvar, 118, 125

Harrington Flock screener, 15
Health Insurance Council, 45
Hematogenous siderosis, 164
Hematoxylin, 168
Hemorrhage, 154
Himly, Karl, 125
Hospital rounds, solo practice, 16–17
Hypertension, 83–84
Hypotony, 242–243, 250

Income, 41–42
  group practice, 37–38
Inflammatory changes, 155–156
Injury
  cause of, 143–145
  incidence of, 138–141
  management problems, 260–261
  nature of, 147–152
    in anterior chamber, 148–149
    chemical, 151–152
    in ciliary body, 150
    entry through closed lids, 147–148
    entry through open lids, 147
    in lens, 149
    miscellaneous foreign bodies, 151
    in posterior chamber, 149–150
    transient foreign bodies, 151
    in vitreous, 150–151
  nonoccupational, 268
  primary factors, 257–260
Inner pole magnet, 233–235
Inpatient administration, 87–93
  cost accounting, 90–91
  cost control, 90–91
  management, 89–90
  medical staff relationship, 91–92
  projection, 92–93
  public relations, 92

Instruments, 117–131
campimeter, 124–125
for extraction of intraocular nonmagnetic foreign bodies, 241
the future, 130–131
gonioscope, 126–127
gripping, 147–148
keratometer (ophthalmometer), 127–128
ophthalmic, 104
ophthalmoscope, 117–118
perimeter, 123–124
refraction unit, 121
retinoscope, 118–119
slit lamp, 125–126
test type, 121–123
tonometer, 128–130
the trial case, 119–120
Insulin, 84
Insurance, 45, 64–65
Insurance agent, role of, 34–35
Intraocular foreign bodies, 133–277
accurate localization, 211–212
bright light operative localization, 205–209
glass fiber diaphanoscope, 206–207
transillumination, 207–208
clinical recognition, 171–179
history, 172
signs, 173–179
symptoms, 173
electronic localization, 193–198
apparatus, 294–295
design considerations, 195–196
effect of a conducting body, 197–198
performance achieved, 196–197
hand-hammer-caused, 144
incidence of, 137–146
cause of injury, 143–145
injury, 138–141
legal aspects, 271–277
compensation, 272
liability, 271–272
medical examinations, 272–277
medical reports, 272–277
the magnet, 231–235
inner pole, 233–235
Mellinger's original apparatus, 232–233
magnet extraction, 213–229
anesthesia, 215
anterior route removal, 217–220
choice of magnet, 215–217
complications, 229
diathermy, 228
exit route, 214
posterior route removal, 220–228
postoperative course, 229
removal plan, 214–215
nature of injury, 147–152
in anterior chamber, 148–149
chemical, 151–152
in ciliary body, 150
entry through closed lids, 147–148
entry through open lids, 147
miscellaneous foreign bodies, 151
in posterior chamber, 149–150
transient foreign bodies, 151
in vitreous, 150–151
nonmagnetic, 237–255
in the anterior chamber, 239–246
case history, 237–238
clinical findings, 237–238
incidence of, 141–143
indications for surgery, 238–239
in the posterior segment, 246–251
prognosis, 252
results of extractions, 251
prevention, 265–269
effect of automation, 267–268
goggles, 266–267
nonoccupational injuries, 268
regulations in the United Kingdom, 265–266
Wise Owls Club, 266

prognosis, 257-263
management problems, 260–261
primary injury factors, 257–260
saving the eye, 261–263
saving visual function, 261–263
retained, 153–170
artefacts, 169
cilia, 166
fibrosis, 160–161
granuloma, 156–160
hemorrhage, 154
inflammatory changes, 155–156
macroscopic investigation, 167
mineral materials, 166
organic materials, 166
ossification, 160–161
phthisis bulbi, 160–161
radiological examination, 167–168
retinal detachment, 156
staining, 168–169
undiagnosed cases, 161
use of photography, 168
ultrasonic localization, 199–203
illustrative cases, 200–202
principle of operation, 199–200
technique, 200
x-ray localization, 181–191
determining diameter of the globe, 182–183
geometrical constructions, 189–191
methods of, 183–189
radiography objectives, 182
reference point, 183
Iris, nonmagnetic foreign body in, 244–245
Iron, 162–166

Jackson, Edward, 120

Kayser-Fleischer ring, 152
Keeler, Charles, 118
Keeler Low Visual Activity, 100
Keratometers, 127–128
Keratometry, 262
17-Keto corticoids, 83
17-Ketosteroids, 83

Law, Frank, 122–123
Lawyer, role of, 35–36
Legal adviser, 42–43
Legal aspects, 271–277
compensation, 272
liability, 271–272
medical examinations, 272–277
medical reports, 272–277
Lens
with concussion cataract, 258
foreign body in, 149
-induced uveitis, 156
magnet extraction, 217–219
nonmagnetic foreign body in, 245–246
Lens, contact, *see* Contact Lens
Lesions from surgical removal, 239
Liability, 271–272
Lids
entry through closed, 147–148
Lister, Sir William, 123

Macroscopic investigation, 167
Maddox rod examination, 15
Magnet extraction, 213–229
anesthesia, 215
anterior route removal, 217–220
choice of magnet, 215–217
complications, 229
diathermy, 228
exit route, 214
posterior route removal, 220–228
postoperative course, 229
removal plan, 214–215
Magnets, 231–235
choice of, 215–217
inner pole, 233–235
Mellinger's, 216, 232–233
ring, 216
Marker
procedure for, 186–188
use of, 185

Medicaid, 45
Medical examinations, legal aspects, 272–277
Medical service representatives, 75–77
Medicare, 45, 96
Medication management, 75–79
  drugs in the office, 77–79
  medical service representatives, 75–77
Medicine, socialized, 96
Mellinger type magnet, 216, 232–233
Merz, G., 119–120
Metals, 161–166
Meyrowitz, E. B., 120
Mineral materials, 161–166
Miscellaneous foreign bodies, 151
Music, 31

National Health Service, 96, 100
National Society for the Prevention of Blindness, 138, 139, 141
Nernst lamp, 125
New practice, 104–105
News media, 107–116
  competition, 113–114
  dealing with reporters, 112–113, 114–115
  inconsistencies, 112
  power of the press, 109–110
  public image, 108–109
  public interest, 110–112
  technical jargon, 115–116
Nonmagnetic foreign bodies, 237–255
  in the anterior chamber, 239–246
  case history, 237–238
  clinical findings, 237–238
  incidence of, 141–143
  indications for surgery, 238–239
  in the posterior segment, 246–251
  prognosis, 252
  results of extractions, 251
Nurses, 32–33

Office
  drugs in, 77–79
  examination, record of, 9–10
  group practice
    design of, 28–31
    dividing income, 37–38
    intercommunication system, 30
    leasing versus ownership, 32
    location of, 27–28
    personnel, 32–34
    salaries, 33–34
    size of, 28–31
  physical structure of, 22–23
Ophthalmic assistants, 69–70
Ophthalmic economics, 1–131
  administration, 7–8
    clinical, 7–8
    effective, 8
    research, 7
    teaching, 7
  clinical teaching, 47–51
    obligations, 48–50
    rewards, 50–51
  contact lens practice, 53–74
    assistants, 69–70
    billing, 71–72
    clinical research, 73–74
    evolutionary problems, 53–55
    guarantee certificates, 65–66
    insurance, 64–65
    lost lens replacements, 66–67
    the receptionist, 70–71
    referral to a colleague, 55–56
    refraction room, 68–69
    routine procedure, 63–64
    scleral lens, 72–73
    scratched lens, 67
    soaking solutions, 67
    space, 67–68
    technicians, 56–61
    wetting solutions, 67
  group practice, 25–38
    advantages of, 25–27
    certified public accountant, role of, 34
    design of office, 28–31
    dividing income, 37–38

insurance agent, role of, 34–35
lawyer, role of, 35–36
leasing versus ownership of office, 32
location of office, 27–28
office personnel, 32–34
reaching partnership status, 36–37
selecting new associates, 36–37
size of office, 28–31
inpatient administration, 87–93
cost accounting, 90–91
cost control, 90–91
management, 89–90
medical staff relationship, 91–92
projection, 92–93
public relations, 92
instruments, 117–131
campimeter, 124–125
the future, 130–131
gonioscope, 126–127
keratometer (ophthalmometer), 127–128
ophthalmoscope, 117–118
perimeter, 123–124
refraction unit, 121
retinoscope, 118–119
slit lamp, 125–126
test type, 121–123
tonometer, 128–130
the trial case, 119–120
medication management, 75–79
drugs in the office, 77–79
medical service representatives, 75–77
medicine and the news media, 107–116
competition, 113–114
dealing with reporters, 112–113, 114–115
inconsistencies, 112
power of the press, 109–110
public image, 108–109
public interest, 110–112
technical jargon, 115–116
optician's role, 95–105
contact lens fitting, 103
new practice, 104–105
ophthalmic instruments, 104
the ophthalmologist and, 97–99
partially sighted patients, 99–103
the patient and, 96–97
the practice, 8–11
private practice, 47–51
public image, 39–46
accounting, 41–42
building, 43–44
continuing education, 44–45
delegation of responsibility, 40
finance, 41–42
insurance claims, 45
maintenance of, 43–44
medical-legal adviser, 42–43
personnel, 40–41
public relations, 39–40
scope of, 5–7
solo practice, 13–24
appointments, 13–14
auxiliary help, 18–19
church affairs, 23–24
civic affairs, 23–24
community affairs, 23–24
consultation, 19–20
economics of, 17–18
examination procedure, 15–16
graduate program, 20–22
hospital rounds, 16–17
structure of office, 22–23
surgery, 17
systemic disease responsibility, 81–86
allergies, 85–86
atherosclerosis, 81–83
diabetes, 84–85
hypertension, 83–84
Ophthalmic Trial Case Lens, 120
Ophthalmo-endoscopes, 249
Ophthalmologist
the optician and, 97–99
prescriptions of, 98

Ophthalmometers, 127–128
Ophthalmoscopes, 117–118
Optical houses, billing, 56–58
Opticians, role of, 95–105
  contact lens fitting, 103
  new practice, 104–105
  ophthalmic instruments, 104
  the ophthalmologist and, 97–99
  partially sighted patients, 99–103
  the patient and, 96–97
Organic materials, 166, 239
Ossification, 160–161
Oxford Ophthalmological Congress, 99

Panophthalmitis, 155–156
Paraffin, 168
Partnership
  advantages of, 25–27
  new associates, 36–37
  reaching partnership status, 36–37
  role of the lawyer, 35–36
Patents for contact lens, 53–55
Patients
  benefits of group practice, 26–27
  billing, 56–58, 71–72
  the optician and, 96–97
  partially sighted, 99–103
Perimeters, 123–124
Perls' reaction, 162
Personnel, 40–41
  group practice, 32–34
  medical staff relationship, 91–92
Photography, 168
Phthisis bulbi, 160–161
Physicians Business Bureau, 18
Pitman, Sir James, 122
Posterior chamber, 177–179
  foreign body in, 149–150
  magnet extraction, 220–228
  nonmagnetic foreign body in, 146–251
PR Doctor, 115
Prescriptions, 98
Press, power of, 109–110
Prevention, 265–269
  effect of automation, 267–268
  goggles, 266–267
  nonoccupational injuries, 268
  regulations in the United Kingdom, 265–266
  Wise Owls Club, 266
Prussian blue reaction, 162
Public image, 39–46, 108–109
  accounting, 41–42
  building, 43–44
  continuing education, 44–45
  delegation of responsibility, 40
  finance, 41–42
  insurance claims, 45
  maintenance of, 43–44
  medical-legal adviser, 42–43
  personnel, 40–41
  public relations, 39–40
Public interest, 110–112
Public relations, 39–40
  inpatient administration, 92
Public Speaking (Carnegie), 115

Radio, 31
Radiography, 181–191
  objectives, 182
Radiological examination, 167–168
Receptionists, 32–33
  duties of, 70–71
Referral to a colleague, 55–56
Refraction rooms, 22–23, 68–69
  double, 29
  equipment for, 23
Refraction unit, the, 121
Reliance chairs, 23
Renovascular hypertension, 84
Reports, legal aspects of, 272–277
Research
  administration, 7
  clinical, 73–74
Responsibility, delegation of, 40
Retinal detachment, 156, 262
Retinoscopes, 118–119
Richard Wolf Company, 206

Ring magnet, 216
Rodenstock refractometer, 130
Rotation, finding the center of, 190
Routit, Guilbert, 126
Royalties, 54
Rubeanic acid, 168–169

Salaries in group practice, 33–34
Schiotz tonometer, 15
Scleral contact lens, 72–73
Scratched lens, 67
Secretaries, 32–33
Siderosis, 162–163, 165, 259
  hematogenous, 164
  true, 164
Silicone, 54
Skiascopy, 119
Slit lamps, 125–126
Smith, F. H., 120
Snellen test chart in Arabic, 121–122
Soaking solutions, 67
Socialized medicine, 96
Solo practice, 13–24
  appointments, 13–14
  auxiliary help, 18–19
  church affairs, 23–24
  community affairs, 23–24
  consultation, 19–20
  economics of, 17–18
  examination procedure, 15–16
  graduate program, 20–22
  hospital rounds, 16–17
  structure of office, 22–23
  surgery, 17
Staining, 168–169
Stereophotography, 168
Sweet localizer, 185
Systemic diseases, 81–86
  allergies, 85–86
  atherosclerosis, 81–83
  diabetes, 84–85
  hypertension, 83–84

Teaching
  administration, 7
  clinical, 47–51
    obligations, 48–50
    rewards, 50–51
Technicians
  off the premises, 57–61
  on the premises full time, 56
  on the premises part time, 56–57
  requirements of, 60
Telephones, 23
Television, 247
Tomography, 181
Tonometers, 128–130
  applanation, 15
  Schiotz, 15
Transient foreign bodies, 151
Transillumination, 207–208
Treatment tray, 77–78
Trial case, the, 119–120
Truman, Harry, 109
Tumors, aldosterone-producing, 84

Ultrasonic localization, 199–203
  illustrative cases, 200–202
  principle of operation, 199–200
  technique, 200
Ultrasonograms, 201
Ultrasound, 199–203
United Kingdom
  automation in, 267–268
  overall incidence of injury, 138–141
  regulations in, 265–266
  use of goggles, 266–267
United States of America
  overall incidence of injury, 138–141
  Wise Owls Club, 139, 266
Uveitis, lens-induced, 156

Visual function, saving, 261–263
Vitreous
  foreign body in, 150–151
  magnet extraction, 221–228
  steel in, 155

W. H. Ross Foundation, 129
Walker, Clifford, 123, 124
Wetting solutions, 67
Wise Owls Club, 139, 266

Xerography, 181
X-ray localization, 181-191
  determining diameter of the globe, 182–183
  geometrical constructions, 189–191
  methods of, 183–189
  radiography objective, 182
  reference point, 183

Young, Thomas, 127

Zahn, Johann, 119

Index

Abiotrophy, 500
Accommodation, 444–445
Agnosia, 358, 389
Agraphia, 358, 361, 389
Akalculia, 389
Alexia, 359, 361, 389
Amaurosis fugax
  in brain tumor, 378, 395–397
  congenital, 500
  hysterical, 461–462
  in occlusive disease, 338–340, 343, 348, 351–352, 355–356, 372
  and psychosomatics, 448, 461–462
Amblyopia, 444, 458–461
Angioma, retinal, 401
Angiospasm, 319, 321, 323, 326, 328, 345, 378, 414
Anisocoria, 446
Anosognosia, 419
Antihypertensive therapy, and retinal pathology, 325–328
Anton's syndrome, 364, 419
Aphasia, 339, 358, 369
Apraxia, 358, 389
Argyll-Robertson pupil, 400
Arteriolar sclerosis, 304–305, 311, 314–315, 323, 325
Arteriole, retinal
  atherosclerosis, 303
  attenuation
    in hypertensive disease, 293, 297–299, 304–305
    in occlusive disease, 342
  caliber irregularities
    in hypertensive disease, 305–306, 326, 328
    in occlusive disease, 340, 346
  copper-wire, 298, 300
  dilatation, 347, 350–351
  embolization in, 338
  focal constriction
    in hypertensive disease, 293, 295, 297–299, 305–306, 308, 318, 320, 326–328
    in occlusive disease, 341, 345
  hyalinization, 319
  leakage, 326
  narrowing
    in brain tumor, 383
    in hypertensive disease, 300, 305–306, 326, 328
    in occlusive disease, 320, 341, 345, 347
  necrosis, 294, 320, 323
  obliteration, 319
  occlusion, 320, 341, 344–346, 348–350, 353, 364
  sclerosis in, 304–305, 311, 314–315, 323, 325
  spasm, 320, 326, 448–449
  structure, 301, 303, 315
Arteriosclerosis, 306, 350
Arteriosclerotic ischemic optic neuritis, 341, 344–345
Arteriovenous caliber relationship, 300–301, 315
Arteriovenous crossing, retinal
  and atherosclerosis, 303
  and hypertensive disease, 308, 311
  and occlusion, 305, 307, 316
  pathology, 298, 314–315
  phenomenon, 295, 300, 305, 307, 323
  See also Gunn's sign

Asthenopia, 453, 455, 457, 474
Atheroma, 338, 347
Atheropoiesis, 303, 314, 328
Atherosclerosis
  and basilar disease, 360, 362–363, 368–369, 371
  and carotid disease, 337–340, 344–345, 349–354, 371
  in hypertensive disease, 303, 305, 323
  and vertebral disease, 360, 362–363, 370–371

Basilar artery
  atherosclerosis, 360, 362–363, 368–369, 371
  and hypertensive disease, 371–372
  occlusion, 339–340, 360, 369, 371
  thrombosis, 360, 370
Benedikt's syndrome, 365
Blepharitis marginalis, 429–430
Blepharospasm, 427–429, 433–434, 414

Carotid artery
  atherosclerosis, 337–340, 344–345, 349–354, 371
  compression, 343
  and diplopia, 339–340
  emboli in, 347–348
  and hemianopia, 339
  and hypertensive disease, 371–373
  insufficiency, 317
  occlusion, 347, 350–351, 353, 359–360, 368
  pulse, bruit of, 341, 343–344
  scintillations, 340
  stenosis, 339–340, 343, 360
  thrombosis, 339, 342–346, 352, 354–356, 360
Cataract
  bilateral, 497
  congenital, 487, 495–500, 507, 509
  and dazzling, 434
  monocular, 341
  unilateral, 352–353, 497–499
Central retinal artery, occlusion of, 303, 305, 313, 341–343, 346–348, 461–462
Central retinal vein
  congestion, 308, 315
  depression, 297
  dilatation, 347, 350, 407
  occlusion, 305–314, 328, 350
Central serous retinopathy, 448-449
Cerebellar artery
  occlusion, 361, 364, 368
  thrombosis, 362
Cerebral sclerosis, 324–325
Chalazion, 430–431
Chiasm, and brain tumor, 391, 393–395, 401
Chiasmal syndrome, 386–387, 392, 394–395, 397, 399, 404
  asymmetrical, 399, 404
Chorioretinitis, 382, 495, 500, 509
Choroid, atrophy of, 500
Choroiditis, 449
Circinate degeneration, 311–313
Clivus ridge syndrome, 385, 389, 404
Coloboma, 495
Coma vigilante, 361, 369
Conjugate deviation, 357, 387
Conjugate gaze
  lateral, 357–358, 402
  palsy, 371, 387, 400, 402
  paralysis, 357–358
  paresis, 400, 402
  weakness, 361, 366–369, 401–402
Conjunctiva
  hyperemia of, 436
  and psychosomatics, 436–438
  venous congestion of, 406
Convergence, 361–368, 400, 402, 439–440
Cornea
  anesthesia of, 433
  epithelial erosions of, 435–436
  haze of, 495, 499, 501
  hypesthesia of, 399, 401
  reflex of, 371, 402

Cotton-wool spot
in hypertensive disease, 298–299, 317–321, 323, 326–327
in occlusive disease, 341, 347, 350

Diabetes, retinopathy in, 341, 350–351
Diplopia
in brain tumor, 398–401, 404
in occlusive disease, 339–340, 361, 364–366, 371
and psychosomatics, 438–439
Dyscalculia, 358
Dysgraphia, 358
Dyslexia, 361, 369
Dysmetria, 371
Dysoric retinopathy, 321

Edema
arteriolar, 350
conjunctival, 433
corneal, 352, 506
macular, 346
of optic disc, 344–345, 377–380, 407
retinal, 298–299, 314–315, 317, 341, 346, 357
Embolization, arteriolar, in carotid disease, 338–339, 341, 347–348, 371–372
Endothelial hyperplasia, 304
Episclera
hyperemia of, 352
venous congestion of, 406
Exophthalmos, 398–399, 406
Exudative angiitis, 321
Eyestrain, 420, 425, 453, 545

Fibrinoid necrosis, 315, 319, 321
Fibrosis, 304
Foster Kennedy syndrome, 376, 386–387, 398
Foveal reflex, loss of, 500

Glaucoma
congenital, 495, 498–501, 506–508
chronic simple, 311–313, 354, 451–453
hemorrhagic, 313–314, 350
hypersecretion, 450–451
intractable, 341, 352–353
and psychosomatics, 413, 426, 449–453
unilateral, 346
Gunn's sign, 305, 323

Hemianopia
altitudinal, 339, 341, 353
binasal, 383
bitemporal, 386–387, 392–393, 395–396, 399, 401, 404
contralateral, 341
homonymous
in basilar–vertebral disease, 361–364, 370, 371
in brain tumor, 388–391, 399, 405
in carotid disease, 341, 348, 353–355, 357
and psychosomatics, 461
in temporal isthmus syndrome, 358–359
monocular, 399
subtotal, 388
temporal, 396–398
Hemihypesthesia, 359
Hemiplegia, 303, 357–358, 365–366
Hemorrhage
in brain tumor, 407
of disc, 379
in occlusive disease, 350
retinal
in benign hypertensive disease, 298, 303, 305, 307, 314
in malignant hypertensive disease, 315–319, 322, 326–327
retrovitreal, 312–313
Herpetic keratitis, 418
Heterotropia, 441–443
Horner's syndrome, 361, 368, 371
Hypermetropia, 381
Hyperopia, 420

Hyperplasia, 315
Hypesthesia, 399, 401
Hypoplasia, 501

Internuclear ophthalmoplegia, 361, 366–369, 371
Involutionary sclerosis, 304–305, 320
Iridocyclitis, 447, 498
Iris
  atrophy, 352, 502, 504
  hypoplasia, 495, 499
  necrosis, 502, 505–507
  neovascularization, 352
  vacuolization of pigment epithelium, 502, 505–506
Iritis, 352, 412–413, 425, 433

Keratitis, and rubella, 433, 501

Lagophthalmos, 402
Lid fissure, widening of, 402
Lindau-von Hippel disease, 401

Macropsia, 344, 390
Macula
  edema in, 346
  occlusion in
    arterial, 347–348
    venous, 310–313
  star figure in, 298, 317, 378–379
Microembolization, 344–345
Microphthalmos, 495, 497–498, 501
Micropsia, 390, 462–463
Microteleopia, 357
Millard-Gubler syndrome, 366
Miosis, 368
Myasthenia gravis, 367, 438
Myoclonus, 361, 369

Neurofibromatosis, 395
Night blindness, 438
Nystagmus
  cerebellar, 401
  dissociated, 361
  gross, 369
  horizontal, 361, 366–368, 390, 401–402, 441
  ocular, 441, 499
  optokinetic, 364, 390, 458
  and psychosomatics, 421
  retractorius, 368, 400
  rotary, 361, 368
  in rubella, 495
  vertical, 361, 368, 371, 401–402

Ocular autostimulation, 502
Oculomotor nerve, 385–386, 404–405
Oculomotor paralysis, 365
Optic disc
  atrophy, 383–384, 386, 394, 396–397, 399, 401, 407
  in carotid disease, 341, 346
  edema, 344–345, 377–380, 407
  hemorrhage, 379
  papilledema, 344–345
Optic nerve
  in brain tumor, 386–387, 396–399
  in carotid disease, 341–343, 346, 348, 353
  compression, 387
  head, 342, 346, 449
  infarction, 341, 348
  inflammation, 450
  in occlusion, 353
  in rubella, 500, 506
Optic neuritis, 378, 450. *See also* Papilledema
Optic radiation, 357, 389–390
Optic tract, compression of, 405
Oscillopsia, 361, 368–369, 371

Papilledema
  in brain tumor, 386, 394, 397, 399, 400–404
  chronic atrophic, 399
  in hypertensive disease, 299, 315, 317, 326–327
  incipient, 380–383
  and increased intraocular pressure, 375–379

of optic disc, 344–345
Papillitis, 378
Parinaud's syndrome, 361, 368, 399–400
Petechiae, 315
Photophobia, 427, 433–435
Phthisis bulbi, 507
Plasmatic vesiculosis, 321
Prethrombosis, 307–308
Pseudoneuritis, 381–382
Pseudopapilledema, 381
Ptosis, 368, 385, 404, 414

Quadrantanopia
in brain tumor, 388–389, 393, 403
in carotid disease, 353, 356

Retina
atrophy of, 508
detachment of, 357, 360
neovascularization of, 315
pigmentation of, 500, 508
in hypertensive disease, 293, 295, 301, 303–304, 314–323, 328, 341, 379
Retinal branch artery, occlusion
in carotid disease, 341, 344–346, 348, 350
in hypertensive disease, 295, 320–321, 328
Retinal branch vein, occlusion, in hypertensive disease, 295, 305, 307–311, 316, 328
Retinitis pigmentosa, 500
Retrobulbar neuritis, 392, 396, 450

Scotoma
in brain tumor, 386–387, 390, 394, 398–399, 403
in carotid disease, 341, 353
in optic neuritis, 378
and psychosomatics, 461
Skew deviation, 366–367, 371
Spherophakia, 502–503
Stagnation, 305, 307, 309, 311, 313, 316
Stenosis, 339–340, 343, 460
Strabismus, 395, 495, 501
Stye, 430–431

Tapetoretinal degeneration, 500
Temporal arteritis, 345
Thrombosis
basilar artery, 360, 370
carotid artery, 339, 342–346, 352, 354–356, 360
cerebellar artery, 363
vertebral artery, 360

Uveitis, 426, 446–447, 450

Vascular sclerosis, 324–325
Vasospasm, 299, 305
Venous stasis, 341, 350–351
Vertebral artery
atherosclerosis, 360, 362–363, 368, 370–371
in hypertensive disease, 371–372
occlusion, 360
thrombosis, 360

Weber's syndrome, 365

Index

Acetazolamide, 605, 686
Adhesives
  alkyl 2-cyanoacrylate, 735–736
  and artificial epithelium, 737
Air injection in aphakia surgery, 681
Air tonometer, 581
Alphachymotrypsin, 689
Amblyopia, 666
Ambulation, postoperative, 682
Amino acids, supply route for, 548
Anesthesia
  for keratoplasty, 673
  topical, 739
Anterior chamber, 668–669
  epithelization of, 707–709
Antibiotics, 721
  postoperative, 683
Antigens
  histocompatibility, 718, 719
  tissue, 717
Antimetabolites, toxic side effects of, 722
Aphakia, 664
  and artificial endothelium, 746
  and conjunctival flap, 639
  grafting in, 668–669
    eye with edematous graft, 738
    successful graft, 688
  operative technique in, 680–682
  vitreous contact in, 711
Applanation tensions, 590
Applanation tonometer, 685, 714
  and epithelial edema, 581
Astigmatism and keratoplasty, 663, 665
Atropine, 681, 683
Augendienst, 637
Autograft, 656, 701
Azathioprine, 719, 722, 723

Bard-Parker knife, 739
Barrier, impermeable, in oxygen deprivation, 630
Barrier function of epithelium, 554
Bartisch, George, 637
Basement membrane, 565–567
  pathological, with basal cell abnormalities, 566
Benzalkonium chloride (Zephiran), 701
Birefringence, 534–535
Birth trauma, 585
Blinking
  pattern, altered, and contact lenses, 620
  rate of, and tear film concentration, 530
  weak, 630
Blood serum as storage medium, 660
Boston Eye Bank, 658
Bowman's layer
  defined, 567
  and pannus, 567–569
Buccal mucosa, transplantation of, 749, 750
Bullous keratopathy, 524, 565–566, 567, 568, 582, 630, 632, 637, 639, 642, 652, 669, 710
  following cataract extraction, 594
  inferior, 562, 593
  severe, 667
  superior, 562, 596
  uniocular, 598

Calcium and endothelium, 553
Carbohydrate, supply of, 547
Carbohydrate metabolism, 545–546
Castroviejo scissors, 677
Cataract extraction, 688–689
  and keratoplasty, 663–664
Cautery
  of Bowman's membrane, 651
  chemical, 651
  electrocautery, 651–652
  Hildreth, 651
  surface, 758
Cetylpyridinium chloride (CPC), 538
Chandler's syndrome, 604
Chemical burns, 602–603, 667, 671, 684, 685, 745, 746
Chloramphenicol-polymyxin, 739
Chondroitin sulfate, 538
Cling, lens, 628
Cocaine, 701, 739
Collagenase, 748
Collagen diseases, 684, 685
Collagen fibers
  of Bowman's layer, 568
  electron microscopic studies of, 576–577
  of pannus, 563, 567, 568
  and retrocorneal membrane, 574
  in stromal edema, 569
Collagen fibrils, 534, 535, 536, 537, 538, 541
Colloid osmotic pressure, 539
Colored rings, 534, 535
Conjunctival bridge, dissection of, 646
Conjunctival flaps, 637, 758
  advantages of, 641–643
  complete, surgical technique for, 644–647
  drawbacks to use of, 643–644
  indications for, 639–640
  partial, vs. complete, 637–639
    with lamellar keratectomy, surgical technique, 647–649
  surgery of, 640–641
    complications of, 649–650
    results, 650–651
Contact lens
  central positioning, 618
  excursion pattern, 616
  higher positioning, 618
  lenticular design, 619, 620
  optimum diameter, 616
  scleral, diagram of, 624
Contact lenses
  as cause of corneal edema, 611
    scleral, 623
  corneal, after keratoplasty, 687–688
  in corneal hydrops, 591
  peripheral flattening, 617, 619
  of poly(methyl methacrylate), 737
Cornea
  defined, 527
  limiting layers of, 549–551
    barrier function of, 550–551
  opaque, replacement of, 747–752
  optical properties of, 531–537
  posterior, disturbances on, and conjunctival flap, 640
  supply route of substances to, 548
Cornea guttata. *See* Guttata
Corneal button, excision of, 678
Corneal curvature, increased, 627
Corneal dystrophy, congenital hereditary, 586–587
Corneal edema. *See under* Edema
Corneal elements, refractive index of, 534
Corneal grafting, penetrating, 586–587
Corneal hydration
  active control of, 551–555
  maintenance of, 549–555
Corneal incision for lower lamellar keratectomy, 648
Corneal layers, hydraulic conductivity of, 550
Corneal prosthesis, penetrating, 670
Corneal stroma. *See* Stroma, corneal
Corneal thickness and contact lens wear, 625–626
Corticosteroids, 608, 680, 722
  postoperative, 683–685

Cortisone drops and scleral lens wear, 634
CPC. *See* Cetylpyridinium chloride
Cyclodiathermy, 687
Cyst, epithelial, 649
  anterior chamber, 708

Dacron in implants, 731
Dacron mesh, 750
Deep-freezing of donor material, 661
Dehydration
  mechanism of, 552
  storage by, 661
Dellens. *See* Pit formation
Descemet's membrane, 575, 582
  and birth trauma, 585, 701
  break in, 602
  and endothelium, 572–573
  excrescences of, 710
  in Fuchs' dystrophy, 587, 588
  in keratoconus, 590–591
  in lamellar keratoplasty, 672
  mechanical difficulties with, following keratoplasty, 704, 705
  in mechanical trauma, 592
  removal of, 677
  separation of, 595–596
Desiccation in air, 661
Desmarres scarifier, 676
Desmosomes, 563
Deturgescence after surgery, 701
Dexamethasone, 603, 684, 739
Diathermy-point applications to cornea, 652
Diffraction phenomena, 533
Diffusion of substances, 542–543
  resistance to, 543–550
Disease(s)
  recurrence of, 716–717
  systemic, and penetrating keratoplasty, 671
Donor
  age of, 657
  death of, interval of enucleation, 662
  medical history of, 658
Donor eyes, evaluation of, 658–659
Donor material
  in penetrating keratoplasty, 656–662
  rejection of, 718
  unsuitable, 699
Donor–recipient junction, poor alignment of, 701–703
Dow Corning Company, 732
Dow Corning Silastic MDX 4-4041, 744
Dry ice, 661
Dystrophies, classic hereditary, 716
Dystrophy. *See* Corneal dystrophy; Fuchs' dystrophy; Lattice dystrophy; Macular dystrophy

Eastman, 910, 735
Edema, corneal, 664
  acute and subacute, 601–603
  causes for, 581
  chronic, 601
    irreversible, 604–608
  contact lens–induced, pathogenesis of, 630–633
  defined, 523
  degree of, as indication for surgery, 666–667
  endothelial, 525
  epithelial, 523–524, 537, 544, 565, 604
    acute, 563
    and basement membrane, 565
    chronic, 568
    and light scattering, 532
  etiological factors following transplantation, 698–720
  graft, prevention of with steroids, 668
    therapy for, 721–723
  inflammatory, 640
  and lamellar keratoplasty, 671
  means of detection of, 624–630
  penetrating keratoplasty in, 655
    technique for, 672
  postoperative, 562, 593, 707
  scleral lens–induced, eradication of, 633–634

Edema, corneal — *Continued*
sectoral, treated with partial conjunctival flap, 642
standard surgical technique in, 674–675
stromal, 524–525, 569, 604, 629, 720
EKG-paste, 607
Electron microscopic examination of edematous corneas, 561
Endothelial damage, 584–599
Endothelial dysfunction, 582, 583, 604
Endothelial rejection line, 575
Endothelial trauma as major cause of graft edema, 700–701
Endothelium
aging, 657
artificial, as fluid barrier, 745–747
beaten-silver, 588
donor, 699
trauma to, 700–701
functional condition of, in scleral lens wear, 632–633
malfunction of, 581–582
as mechanism of dehydration, 552
metabolism of, 546
semipermeability of, 551
Enucleation and cleaning of donor eye, 657–658
Enzymes causing stromal ulceration, 748
Epinephrine, 605
Epithelial damage and penetrating keratoplasty, 670
Epithelium, 562–564
artificial, 736–742, 758
complications of, 742
duration of, 743
indications for, 738
technique for, 738–742
donor, denudation of, 700
and oxygen uptake, 545
regrowth of, 742
as semipermeable membrane, 550
Erosions, recurrent, 640
Erythromycin, 680, 683
Ethicon, 678
Evaporation, accelerated, 606
Extraocular muscle function, loss of, 631
Eye, refractive power of, 527

Fenestration, lens, 633–634
Finger tension, 581
Flieringa ring, 680, 688
Fluid barrier procedures, 742–747
Fluid medium for storage, 660
Foreign body, retained, 592–593
Fuchs, Ernst, 587
Fuchs' dystrophy, 524, 562, 572–573, 587–590, 605, 655, 664
artificial epithelium in, 741
cataract in, 688
conjunctival flap in, 639
keratoplasty for, 703

Glare sensitivity and epithelial edema, 624–625
Glaucoma, 524
acute, 563, 601–602
stromal edema in, 525
acute angle-closure, 582
as cause of graft edema, 714
chronic, 562, 569, 574, 643
conjunctival flap in, 640
colored rings seen in, 534
congenital, 585, 701
corneal edema as sign of, 582
and donor eye, 659
and endothelial guttata, 589
and epithelization of anterior chamber, 707
open-angle, 589–590
and penetrating keratoplasty, 670, 686–687, 713–715
postoperative, 668
in total grafts, 676
and scleral contact lens, 632
therapy for, 722
Glucose, 545–547, 607
in control of hydration, 553
utilization of, 547
Glucose phosphate, 547

Glycerine, 661
  anhydrous, 582, 602, 607–608
  oral, 686
Glycerol dimethacrylate, 734
Glycogen
  epithelial reservoir of, 545
  in epithelium, 547, 563
Glycol dimethacrylate, 734
Glycolysis, 546
Graft rejection, 574–576
Graft(s). *See also* Keratoplasty
  contraindications to, 689
  immunogenic rejection of, 717–720
  size of, in penetrating keratoplasty, 676
  total, 676
Grieshaber Colibri forceps, 678
Grieshaber's Franceschetti trephines, 676
Guttata, 572, 574, 582
  and cataract extraction, 689
  endothelial, 592
    and surgery, 593–594
  incidence of, 588

Haab knife, 680, 681, 745
Haig Streit Slit Lamp, 625
Halo. *See* Sattler's veil
Hemidesmosomes, 565, 567
Hepatitis and donor eye, 658
Herpes simplex, 716
  recurrent, 717
  stromal, 599
Heterograft, penetrating, 656
Hexosemonophosphate shunt, 546, 547
Hospitalization following keratoplasty, 682–683
Hyaloid face, contact with endothelium, 712
Hydration, temperature reversal of, 552
Hydraulic conductivity, 734
Hydrocortisone, 685
Hydrogel membranes, thickness of, 735
Hydrogels in implants, 734–735
Hydrops, 591
  in keratoconus, 602
Hypertonic agents, 757
  trial before surgery, 662, 665
Hypertonic drops, 606
Hyphema, 711, 712, 713

Idoxuridine, 599
IDU, 603
Imbibition of fluid, preoperative, by donor tissue, 699–700
Imbibition pressure, 540, 541, 542, 544, 551
  gradient, 542
Immunogenic rejection, control by chemotherapy, 722
Implant
  alloplastic, materials for, 729–736
  buried mushroom-shaped, as fluid barrier, 745
Infection(s)
  bacterial, 603
  herpetic, 603
  as source of graft edema, 715–716
  viral, 716
Inflammation
  and corneal edema, 597–599, 605
    intraocular, 710
    postoperative, 714
Intralamellar membrane as fluid barrier, 743–744
Intraocular pressure, 540
  in acute glaucoma, 601
  changes in, 581
  decreased, 604–606, 643, 758
  effect on cornea, 543–544
  and extrusion of a prosthesis, 748
  in fluid barrier procedures, 742
  increased, 582–584, 713–715
    in epithelial edema, 632
  and penetrating keratoplasty, 670–671
  postoperative, 685–687
IOP. *See* Intraocular pressure
IP. *See* Imbibition pressure
Iridectomy, 678, 688
Iridocyclitis, 709, 710, 713

Iritis, 597, 709
Irradiation, dangers of, 668

Karo syrup, 607
Keratan sulfate, 538
Keratectomy, segment, and conjunctival flap, 758
Keratitis, 574
  bacterial, 715
  deep, 573
  interstitial, 685, 716
  neuroparalytic, 640
  primary herpetic, 716
  tuberculous, 716
Keratoconus, 590–591, 701
Keratocytes, 569–571
Keratometry, 626–627
Keratoplasty
  lamellar, 656, 671–672
    preservation for, 661
  later, 642
  penetrating, 586, 589, 596, 655, 697
    avoidance of, 642
    indications for, 662–672
    technique for, 672–682
    viable material, 656
    vitreous contact in, 712
  postoperative care, 682–688
  prognosis for, 662
Keratoprosthesis, 749, 750
Keratouveitis, chronic herpetic, 598

Laceration and edema, 591
Lactate, accumulation of, 546
Lactic acid dehydrogenase (LDH) isozymes, 546, 547
Lattice dystrophy, 717
Lattice theory, 577
LDH. *See* Lactic acid dehydrogenase
Leahey forceps, 679
Lens, perforation of, 633–634
Leukemia and donor eye, 658
Leukopenia, 723
Lid anomalies, 745
Lid muscle tone, decrease in, 630
Light scattering, 531–533, 535–537, 577
Light transmission through cornea, 531
Lyophilization, 661

Macular dystrophy, 717
Manometer, 540
Massachusetts Eye and Ear Infirmary, 682
Medications
  as cause of epithelial edema, 599
  dangers of, 701
Meibomian glands, 528, 529
Membrane. *See also* specific names, as Basement membrane; Retrocorneal membrane
  postgraft, 706
Mercury oxycyanate, 701
Meshworks in implants, 731
Metabolism and nutritional supply, 544–549
Metachromasia, 530
Methyl ester, 735
Microscope. *See also* Electron microscopic studies
  operating, use in keratoplasty, 673
Miosis prior to keratoplasty, 714
Miotics, 683
Moist chamber method of storage, 659–660
Monomers HEMA and GMA, 734
Mucopolysaccharide, 530
Mydriatics, 680, 714
  postoperative, 683

Na-K-ATPase and hydration of cornea, 554
Negative pressure, presence of, in scleral lens wear, 633
Neo-Synephrine, 681, 683
Neovascularization in swollen corneas, 572
Nutritional supply, disturbances, 548–549

Oil, storage in, 660, 661
Oily layer, superficial, 528

Opacification
immunogenic, 719
residual after flap removal, 650
Ophthalgan, 608
Osmotherapy, 757
topical, 606–608
Osmotic agents, 589
Osmotic dehydration of the cornea, theory of, 551
Osmotic imbalance, 523
Osteo-odonto-keratoprosthesis, 749
Ouabain, 551, 554
Overwearing abrasions, 613, 614
Oxygen, and volume and quality of tears, 630
Oxygen deprivation in corneal edema, 630–632
Oxygen needs of the cornea, 614
Oxygen permeability of implant material, 732
Oxygen supply, 544–545
Oxygen tension, 545
of the precorneal fluid, 611

Pachometers, 582, 625
Pain as indication for surgery, 666
Pannus, 567
Parallax in visualizing contact lens edema, 613
Pars plana aspiration, 680–681
Perforation, inadvertent, in conjunctival flap, 650
PGMA. *See* Poly (glyceryl methacrylate)
Phakia, 668–669
operative technique, 677–680
PHEMA. *See* Poly(2-hydroxyethyl methacrylate)
Phospholine Iodide, 606, 687
Photophobia as symptom of contact lens edema, 613
Phthisical eyes, 605
Pilocarpine, 605, 673, 683, 687
Pinocytosis in endothelium, 554
Pit formation, 529, 542
Pleomorphism, 572
PMMA. *See* Poly(methyl methacrylate)
Poly(dimethylsiloxane), 732
Poly(ethylene terephthalate). *See* Dacron
Poly(glyceryl methacrylate), 734
Poly(2-hydroxyethyl methacrylate), 734
Polymers
used in corneal implants, 730
water absorption and refractive index of, 731
Poly(methyl methacrylate) for corneal implant, 729–731
Polyoxyethylene and silicone oil, 607
Polysaccharides, 541, 542
in corneal stroma, 538–539
Poly(tetrafluoroethylene). *See* Teflon
Polyvinyl pyrrolidone (PVP), 607
Prednisolone, 603, 685
Preglaucoma, 590
Preoperative treatment for keratoplasty, 673
Preservation, long-term, 661
Pressure. *See* specific names, as Imbibition pressure; Intraocular pressure; Swelling pressure
Pressure relationship at the endothelial surface, 541
Prostheses, through-and-through, 747–752, 759
Prosthesis, collar-button–shaped, 751
Protein synthesis, rate of, 548
Ptosis following conjunctival flap, 650
Pupillary block
postoperative, 686
as source of glaucoma, 714
Purine analogues, 722
PVP. *See* Polyvinyl pyrrolidone

Refraction, postoperative, 687–688
Refractive index
of corneal elements, 534
and transparency, 535
Respiration, 544–545
Retinoblastoma in donor eye, 658

Retrocorneal membrane, 574, 704–707
Retroillumination, 624
Rheumatoid arthritis, 702
  and penetrating keratoplasty, 671
Rosacea, 671, 685
Rosacea keratitis, 702
Rubber, silicone. *See* Silicone

Sattler's veil, 533, 611
Scatter, sclerotic, 624
Schiotz tonometry, 581
Semipermeability, perfect, defined, 551
Septicemia and donor eye, 658
Silastic, 732
Silicone
  as fluid barrier, 744
  in implants, 732–733
Sjögren's syndrome, 630
Slit lamp evaluation of epithelial edema, 624
Slit lamp examination, 581–582
  of donor eyes, 658
  postoperative, 682
Slit lamp technique of sclerotic scatter, 612
Sodium chloride, 606
SP. *See* Swelling pressure
Steroid requirements, scheme of, following keratoplasty, 684
Steroids, 603
  in inflammation, 599
  systemic, 723
Steroid treatment, postoperative, 667–668
Stillborn, unsuitable as donors, 657
Stitch abscess, 715
Storage of donor materials, 659–662
Storage, length of, 661–662
Stroma, corneal, 538–544
  dehydration of, 715
  edematous, 569–572
  flow of fluid in, 540–542
  hydration of, 538–539
  movement of substances in, 542–543
  transparency of, in glaucoma, 583
  vascularized, 571
Stroma scatter, 532–533
Structure, relationship to transparency, 576–578
Surface-active agents, 607
Surface evaporation, decrease in, 632
Surgical measures and endothelial dysfunction, 584
Suture removal, 687
Sutures
  inaccuracy in placement of, 702
  infection around, 715
  interrupted, 678
Swelling
  corneal, 551
    effect on image formation, 533
  epithelial, 561–562
  stromal, 532, 538–539, 549, 562
Swelling pressure, 539–540
Synechiae, anterior, 710–711
Syphilis
  congenital, 716
  and donor eye, 659

TCA. *See* Tricarboxylic acid
Tear exchange and contact lens, 615
Tear film
  evaporation from, 529
  precorneal, 527-531
  tonicity, 523, 530
    increase in, 606–608
Tear fluid, 528
Tears, 527–531
  circulation of, and prevention of epithelial edema, 627
  flow of, beneath contact lens, 615
  human, glucose in, 547
Tear volume, decreased, 630, 745
Teflon in implants, 731
Temperature for storage, 660
Thickness-hydration relationship in corneal swelling, 539
Touch grinding, 633
Transparency, 535–537

Trauma, 574
and chronic edema, 602
direct and indirect, 640
mechanical, 591–593, 704
surgical, 593–597
and conjunctival flap, 639
Trephining the donor eye, 676–677
Tricarboxylic acid (TCA), 546
cycle, 547, 553
Turgescence, corneal, 697

Ulcers, peripheral, 640
Uveitis, 709–710
anterior, 573, 574, 706
chronic, 640
chronic, and penetrating keratoplasty, 671
and donor eye, 659
therapy for, 722

Vannas scissors, 678, 687
Varicella, 716
Vascularization, 718, 720
in conjunctival flap, 650
and penetrating keratoplasty, 667–668
of retrocorneal membrane, 706–707
stromal, 723
Venting of contact lenses, 614–621
Visual acuity
before and after artificial epithelium, 741
in epithelial edema, 628–630
and keratoplasty, 662–666
and light scatter, 533
Vitamin C therapy, 608
Vitreous, removal of, 680–681
Vitreous contact, 711–712
Vitreous face adhering to endothelium, 594–595

Warts, Hassal-Henle, 572
See also Guttata
Water flow
in cornea, 530–531
resistance to, 550
in plane of the cornea, 541

Xylocaine, 644, 673

Zeiss operating microscope, 673
Zephiran. *See* Benzalkonium chloride

Index

Abdominal anomalies in trisomy E, 870, 872
Aberrations
  chromosomal, 787–788
    action of, 794
    colobomatous lesions of eyeball, 806–809
    group A (1–3), 839–844
    group B (4–5), 844–848
    group C (6–12), 848–849
    group D (13–15), 850–868
    group E (16–18), 868–879
    group F (19–20), 879–880
    group G (21–22), 880–884
    numerical, 773, 785–787, 789–791
    structural, 773, 791–793, 886–887
  gonochromosomal, 809
Abiotrophy, 911
Abnormalities
  and complicated anophthalmia, 806
  in partial monosomy 21–22, 884
  See also Anomalies; Malformations
Abortion
  and chromosomal aberration, 789
  and trisomy E, 871
Achromatopsia, 999, 1000
  and recessive optic atrophy, 999
Adiposogenital syndrome, 982
Age and Leber's disease, 1025
Allelomorph, normal (recessive), 774, 776
Amaurosis, congenital. *See* Amblyopia
Amblyopia, 929
Amino acid metabolism, disturbance of, 921–922
Aneuploidy, 789
Anomalies
  bilateral, in idiopathic retinoschisis, 982
  cerebral, in Leber's disease, 942
  and chromosomal aberrations, 794, 888
  congenital, and trisomy E, 871
  in cryptophthalmia, 820–822
  in deletion D, 867–868
  in deletion E, 876, 878
  of fundus, in choroideremia, 950
  in Hooft's syndrome, 916
  in inversion A, 843
  in mosaicism D, 868
  ocular, frequency in trisomy D1, 858
    in partial trisomy B, 844, 845
    in trisomy E, 869, 872
    in trisomy 21 or 22, 884
  in orodigitofacial syndrome, 839–840
  psychiatric, in Leber's disease, 940
  skeletal, in Leber's disease, 942
    in partial trisomy B, 846
  systemic, case history, 824–826, 829–831
  in translocation A, 842
  and trisomies, 790, 806
    partial trisomy, 840
    partial trisomy C, 849
    partial trisomy D1, 865–868
    trisomy D1, 807, 858, 862–864
    trisomy E, 877

Anomalies — *Continued*
See also specific names, as Abdominal anomalies; Cardiovascular anomalies
Anophthalmia, 798, 805–806
bilateral, 798
colobomatous, 805
complicated, 806
pure, 805
recessive inheritance of, 805
Aplasia, of macula. *See* Macula, aplasia of
Arachnoiditis, opticochiasmatic, 1005
Arhinencephaly in deletion E, 878
Ataxia, hereditary, and optic atrophy, 1005
ATP levels in Hooft's syndrome, 917, 919, 920
Atresia
of anus, 822, 885
in trisomy 22, 882
of larynx, 822
vesical, 822
Atrophy, optic
hereditary, 930, 999–1003
dominant, cases of, 1006–1013
evolution of, 1005–1006
dominant autosomal, 1004–1005
recessive autosomal, 999–1003
heredofamilial infantile (Behr's complicated type). *See* Behr's syndrome
Autopsy
in case of trisomy D1, 853
and visceral anomalies, 863
Autosomal recessive character
Cockayne's syndrome as, 879
in cryptophthalmia, 819
and retinal detachment, 965
Autosomal recessivity and optic atrophy, 1003
Autosomes, 774, 787
absence of segregation of, 789
Axis
in optic atrophy, blue-yellow, 1005, 1013
green-red, 1005

Balanohypospadias in partial monosomy 21–22, 884
Bardet-Biedl syndrome, 783, 784
Bassen-Kornzweig syndrome, 916
Behr's syndrome, 930, 1013–1016
as autosomal recessive trait, 1014
Blepharophimosis
in deletion E, 876
in trisomy D1, 858
in trisomy E, 869
Blindness
complete, and optic atrophy, 1002
congenital, 931, 936, 939
and complicated microphthalmia, 804
cortical, 929
night, 957
Blue perception, deficiency in, in dominant optic atrophy, 1005
Bowman's membrane, thick, in trisomy D1, 854
Bruch's membrane absent in Leber's disease, 944
Brushfield's yellow spots in Langdon-Down's syndrome, 881
Buccal anomalies, 839

Carbohydrate metabolism, disturbance of, 911–912, 914, 920
Cardiac malformations in trisomy D1, 863
Cardiovascular anomalies in trisomy E, 870, 873
Carotenoids and development of normal retina, 912
Carriers
detection of, 784
females as, 779, 780, 781
in choroideremia, 782, 950–963
in conjunctival melanosis, 960
in hemophilia, 1028-1029
in Leber's disease, 1027–1030, 1031, 1033, 1034
and monozygotic twins, 1021

Cataract, 861
bilateral, punctiform nuclear, in deletion B, 878
in trisomy 22, 882
in indeterminate polysomy, 885
in Langdon-Down's syndrome, 881
in partial trisomy D1, 865
in trisomy D1, 859
Cat's cry disease, 806, 846, 847, 848
Cells
spermatogenic, destruction by iodoacetate, 914
visual, destruction by iodoacetate, 913
Central vision in Leber's disease, 1017
Centromere, 787–788
Cerebral malformations in trisomy D1, 863
Cerebral paralysis and partial trisomy C, 849
Chatzinoff et al., hypothesis of, 913
Chorioretinal atrophy, 957
Chorioretinal degeneration
hereditary, metabolic origin of, 911
progressive, 939
case histories, 951–962
Chorioretinitis, syphilitic congenital, 940
Chorioretinopathy, salt-and-pepper type, 949, 950
Choroid
coloboma of, 798, 861
in indeterminate polysomy, 885
in trisomy E, 869
colobomata of, bilateral, 885
Choroidal sclerosis, 957
features of, 934
generalized, in Leber's disease, 934
peripapillary, in Leber's disease, 934
Choroideremia
defined, 949
in Leber's disease, 935
in men, 781, 782
sex-linked, 956
See also Chorioretinal degeneration
Choroidosis, myopic, and retinal detachment, 966
Chromosome(s)
abnormal number of, 773
acrocentric, 793
homologous. *See* Autosomes
inactive X, 785
non-sex. *See* Autosomes
Philadelphia chromosome, 884
ring. *See* Deformation, annular
seven groups of, 788
sex. *See* Gonosomes
X and Y, 778–780
in Leber's disease, 1032
Chromosome B
trisomy, for long arm of, 845–846
for short arm of, 844–845
Chromosome 5, deletion of. *See* Cat's cry disease
11-cisretinene, 912, 913
Cleft lip
double, in trisomy E, 874
in orodigitofacial syndrome, 840
in trisomy D1, 862
Cleft, palatal, in trisomy D1, 862
Clinodactyly of little finger, 862
in deletion E, 876
in trisomy E, 869
Clitoris, hypertrophy of, in Marfan's syndrome, 887
Cockayne's syndrome, trisomy F in, 879–880
Coloboma
chorioretinal, and coloboma of iris, 799, 800
and closure of optic cleft, 797
partial, 799
See also Choroid; Eyelid; Iris; Optic disc; Optic nerve; Uvea
Color vision in optic atrophy, 1004–1005
Consanguinity. *See* Parents, consanguineous
Cornea plana, 852, 853, 854
Craniofacial anomalies
in trisomy D1, 862, 863
in trisomy E, 869, 871

Cryptophthalmia
abortive forms, 818–819
case histories, 823–831
familial manifestations, 819–820
incomplete, atypical or partial forms, 818
as symptom of malformative syndrome, 831
typical, 817–818, 826
Cryptorchidism, 823
Culture media and protein metabolism, 912
Cyclops in deletion E, 878
Cystine, accumulation of. *See* Cystinosis
Cystinosis, case history, 922
Cystinuria, 921
Cystoid degeneration in hypermetropia, 970
Cystogenetic examination, 888
Cystogenetics in diagnosis of trisomy, 790
Cytomegalic inclusion bodies in trisomy E, 873

Dark adaptation in Leber's disease, 1018
Deafness, neurogenic, and optic atrophy, 1002
Deformation, annular, 793, 843
Degeneration. *See specific types, as* Chorioretinal degeneration
Deletion of chromosome, 792, 793, 808
deletion B, 846–848
deletion C, 849
deletion D, 867–868
deletion E, 876–879
deletion G, 884
Deletions, lethality of, 889
Dermatoglyphic anomalies
in deletion E, 878
in trisomy D1, 864
in trisomy E, 870
Descemet's membrane, underdeveloped, 854
Detachment, retinal. *See* Retinal detachment
Diabetes and optic atrophy, 1002
Digital anomalies, 839, 841
Disease
recessive, characteristics of, 777–778
graver than dominant disease, 782
Disomy, partial, 867
Dithizone and retinopathy, 914
DNA, modification of, and mutation of genes, 773, 783
Dominance
autosomal, orodigitofacial dysotosis, 840
irregular, 775
pseudodominance, 775, 800
in optic atrophy, 1000
of retinal detachment, with myopia, 969
with or without myopia, 972
Dominant character defined, 774
Dwarfism
in deletion G, 884
in Hooft's syndrome, 917
and optic atrophy, 1002
in partial monosomy 21–22, 884
Dyscephalic signs of systemic malformations, 820–821
Dyscephaly, 829–832
Dyschromatopsia
acquired, 1005, 1013
in Leber's disease, 1018
and recessive optic atrophy, 999
Dysmorphosis
craniofacial, in cat's cry disease, 846–847
in partial trisomy B, 844
in translocation 4/5, 845
facial, in deletion E, 878
Dysostosis
multiple, of Pfaundler-Hurler, 920, 923
orodigitofacial, 839, 841, 842

Dysplasia
retinal, in trisomy D1, 859–862
Reese's. *See* Reese's retinal dysplasia
Dysplastic body build and coloboma of uvea, 800
Dystrophy of retina in Leber's disease, 936

Ear(s)
malformations of, 821, 824–825, 830, 832, 862
anomalies in trisomy E, 872
low-set, in deletion E, 876
in partial monosomy 21–22, 884
middle ear, hypoplasia of, 879
Ectropion in Langdon-Down's syndrome, 881
Edwards' syndrome. *See* Trisomies, trisomy E
Electroencephalogram in Leber's disease, 940–941
Electrooculographic examination in Leber's disease, 937
Electroretinographic examination, 827–829
b-wave of 200μ V, 828
in choroideremia, 950
in diagnosing Leber's disease, 936–937, 946, 1019
evolution of, in case of Leber's disease, 938
of normal and cryptophthalmic eye, 828
in optic atrophy, 930
in retarded myelinization, 930
Embden-Meyerhof cycle, 914
Embryo, factors producing malformations, 786-787
Emmetropes, retinal detachment in, 970–971
Encephaloophthalmic dysplasia. *See* Dysplasia, retinal
Encephaloophthalmosplanchnic dysplasia. *See* Dysplasia, retinal
Enzymatic disorders and hereditary chorioretinal degeneration, 923
Enzymes and malformations, 794
Epicanthus
in deletion E, 879
in Langdon-Down's syndrome, 881
in trisomy D1, 858
in trisomy E, 869
in trisomy 22, 882
Epileptic fits in coloboma of iris, 843
ERG. *See* Electroretinographic examination
Evocators, 786
Expressivity, 781, 782, 784
Extremities, anomalies of, in trisomy D1, 862
Eyeball, microphthalmic, 802, 826
Eyelid(s)
absence of, 817, 831
coloboma of, 823–824, 826
malformation of in trisomy E, 869

Facial anomalies, 839, 841
Family, examination of, 784
Fats, metabolism in Hooft's syndrome, 917
Females
as carriers. *See* Carriers, females as and choroideremia, 950–962
pathological gene in, 781
sex chromosomes in, 778
Fibroplasia, retrolental, 930, 931
Finger(s)
fixation in flexion, 869
index, short, in partial monosomy 21–22, 884
Foot, anomalies of, in trisomy E, 873
See also Hallux varus; Rocker-bottom foot
Fragmentation of chromosomes, 791
Franceschetti, oculodigital sign of, 826

Fundus, ocular
apparently normal, in Leber's disease, 932–33
choroidal nevus, 961
in choroidal sclerosis, 959
in choroideremia, 954, 958
albinoid, 952, 953
salt-and-pepper type, 955
flavimaculatus, 961

Gametes, formation of, 774, 789
Gargoylism. *See* Dysostosis, multiple, of Pfaundler-Hurler
Gaucher's disease, 915
Gene(s)
on autosomes, 774–778
normal, 774
pathological, 774
and hereditary disease, 783
pleiotropic, 783, 784
polyphenic, 784
recessive, 776
incomplete recessiveness, 781
man crossed with normal woman, 780
sex-linked inheritance, 780
on sex chromosomes, 778–781
varied phenotypical manifestations of, 783–787
X-linked, 785
See also Expressivity; Penetrance; Specificity
Genital organs, malformations of, 821–822, 825, 826, 830, 831, 832–833
in trisomy D1, 863
in trisomy E, 872
Genitourinary anomalies in trisomy E, 870
Genome
with abnormal karyotype, 773
haploid, 773
Glaucoma
congenital, in trisomy E, 869
in pure microphthalmia, 803
Glycolysis
anaerobic, of retina, 911
disorder of, in Hooft's syndrome, 917
enzymatic block of, 914
effect of iodine salts, 913
effect of sodium bromacetate, 914
Gonosomes, 778–781, 787
Growth retardation
in deletion E, 878
in Hooft's syndrome, 916

Hallux varus, 851, 862
Hand(s), anomalies of
large, in deletion E, 876
in trisomy E, 873
deviation of axis in, 875
Haploidy, 787
Hemangioma, giant, in trisomy 22, 884
Hemeralopia and idiopathic retinoschisis, 980–983
Hemophilia and Leber's disease, 1035
Hereditary detachment of the retina. *See* Retinal detachment, hereditary
Heredity
and cryptophthalmia, 819-820
and environment, 786-787
and Hooft's syndrome, case histories, 917–920
and Leber's disease, 943–944, 1021–1035
cytoplasmic, 1033–1035
dominant autosomal, 1032–1033
sex-linked, 1023–1032
mendelian. *See* Mendelian heredity, 774
sex-linked, and choroideremia, 962–963
recessive, 1024
Hernia
bilateral inguinal, in partial monosomy 21–22, 884
umbilical, 882
Heterozygote, defective, 774
and Leber's disease, 1029
Heterozygous individual, crossing for recessive defect, 776

Heterozygous women
active genes in, 785
and choroideremia, 781
crossing with normal man, 779
Histopathological examinations in trisomy D1, 861
Homozygote
normal, 774, 775, 777
pathological, mating with normal homozygote, 777
Homozygous individual, 776
Homozygous women
active genes in, 785
and idiopathic retinoschisis, 979
Hooft's hypolipidemic syndrome, 916–920
differing from Bassen-Kornzweig disease, 916
pathogenesis, 916–917
Hyalin plaques in Leber's disease, 945, 946
Hyalinosis cutis et mucosae, 920–921
Hyaloidoretinal degeneration, 974
Goldmann-Favre's, 980–983
Wagner's, 970, 977, 983–987
Hyperaminoaciduria, 922
Hyperdiploidy. *See* Polysomy
Hyperflexion of hand and fingers, 862
Hyperkeratosic nevus of face and skull in Leber's disease, 942
Hypermetropia, 802
retinal detachment in, 970
Hypertelorism
in deletion E, 876, 879
in indeterminate polysomy, 885
in Langdon-Down's syndrome, 881
in Marfan's syndrome, 887
in trisomy E, 869
Hypertonia
in partial monosomy 21–22, 884
in trisomy E, 871
Hypocholesterolemia in Hooft's syndrome, 919
Hypoploidy. *See* Monosomy

Idiocy
amaurotic, 915
Mongolian. *See* Langdon-Down's syndrome; Mongolism
Imbecility, 839
in Leber's disease, 940
See also Mental retardation
Inactivation theory of Mary Lyon, 784–785
Inheritance
autosomal, dominant, 774–775
recessive, 776–778
intermediate, 781–783
sex-linked, 778–781
Insertion of chromosome piece, 792
Intermediary metabolism, disturbances of. *See* Oxalosis
Intestinal malformations
in trisomy D1, 863
in trisomy E, 873
Inversion of chromosome piece, 792–793
inversion A, 842–843
Iodine salts and experimental retinal alterations, 913–914
Iodoacetate, 913
Iris
coloboma of, 798–801, 806, 865
associated with other abnormalities, 799
and inversion A, 843
left, in indeterminate polysomy, 885
in retinal dysplasia, 861
in trisomy D1, 807, 858
and trisomy E, 809, 869
colobomata of, bilateral, 866, 885
in trisomy 22, 882
heterochromia of, 957

Japanese and Leber's disease, 1028, 1030, 1033,
Juvenile retrobulbar neuritis, Leber's. *See* Leber's disease

Karyogram, normal, 788
Karyotype
  anomaly of, 889
  defined, 791
  interpretation of, 888
  normal, with trisomic symptoms, 790
Keratoconus in Langdon-Down's syndrome, 881
Kidney
  absence of, in indeterminate polysomy, 885
  double, in trisomy E, 873
  malformation of, in indeterminate polysomy, 885
Kinetochore. *See* Centromere

Langdon-Down's syndrome, 849
  ocular signs in, 880–882
  See also Mongolism
Leber's disease, 931–946, 1003
  age of onset, 1017
  associated signs, 1019
  confused with other conditions, 938–939
  diagnosis of, 936–940
  dominant inheritance, 943
  evolution of, 1017–1018
  functional symptoms, 932
  histopathology of, 944–946
    case histories, 1020–1021
  men vs. women affected, 1016–1017
  neurological and general symptoms, 940–943
  objective signs, 932
  and optic atrophy, 1003, 1004
  systemic and neurological examinations, 1019–1020
Le cri du chat. See Cat's cry disease
Leucocyte cultures, blood, in deletion G, 884
Leukemia
  acute myeloblastic, 884
  granulocytic myeloid, 884
Lignac-Fanconi disease. *See* Cystinosis
Lipid metabolism, disturbances of, 915–917
Lipidosis, Refsum's syndrome as, 916
Lipoidproteinosis, 920
Lipoproteins
  in Hooft's syndrome, 919
  β-lipoprotein, absence of, 915
Lossen, law of, and Leber's disease, 1029
Lyon, Mary, 784–785

Macroglobulinemia
  and indeterminate polysomy, 885
  Waldenström's, 885, 888
Macula, aplasia of, 803
Macular changes in Leber's disease, 935
Macular region in choroideremia, 950
Males
  choroideremia in, 949–950
  and Leber's disease, 1026, 1027
  pathological gene in, 781
  sex chromosomes in, 778, 779
Malformations
  and cryptophthalmia, 820–822
  and complicated microphthalmia, 803–804
    in trisomy D1, 858–862, 868
  in partial trisomy C, 849
  and trisomy E, 808–809, 869–873
  visceral, in retinal dysplasia, 859
  See also Anomalies
Malformative syndrome, 817
  main symptoms, 831–833
Marbling. *See* Marmoration
Marfan's syndrome, 886–887
Marie, Pierre, syndrome of, 1014
Marmoration, 934
Marriages, consanguineous. *See* Parents, consanguineous
Meckel's diverticulum in partial monosomy 21–22, 884
Megalocornea in trisomy E, 869

Mendelian heredity, 774–787
  classic, and cause of disease, 773
  and colobomatous lesions of the ocular globe, 797–806
Mental deficiency
  and complicated microphthalmia, 804
  in partial monosomy 21–22, 884
Mental retardation, 839
  and coloboma of uvea, 800
  and complicated microphthalmia, 804
  and cryptophthalmia, 822
  in deletion E, 876, 879
  in Hooft's syndrome, 916, 917, 919
  in indeterminate polysomy, 885
  and optic atrophy, 1002
  in orodigitofacial dysostosis, 842
  and trisomy D1, 864
  and trisomy E, 808, 871
  See also Mongolism
Mesentery, common, in partial monosomy 21–22, 884
Mesoderm
  intraocular primary, persistence of, 860
  and trisomy D1, 850
Metabolism
  disturbances of, 911–913, 914–923
    in Leber's disease, 942
  See also specific names, as Amino acid metabolism; Carbohydrate metabolism; Lipid metabolism; Protein metabolism
Metaphase, chromosomes of cell in, 787
Microcephaly in trisomy E, 874, 876
Microchromosome, 792
Microphthalmia, 802–804
  with aniridia, in trisomy D1, 864
  bilateral, 797, 806, 807, 861, 867, 868
    with blindness, 798
  with coloboma of choroid and optic nerve, 798
  and coloboma of iris, 799, 800
  colobomatous, 802
  complicated, 803–804
  with glaucoma and cataract, 798
  in indeterminate polysomy, 885
  in partial trisomy C, 849
  in partial trisomy D1, 865
  pure, 802–803
  in trisomy D1, 852, 853, 858
  unilateral, 868
Microsymptoms, detection of, 784
Mitosis, abnormal, 789
Mongolism
  and trisomy G, 809
  trisomy 21 in, 790, 880
  See also Langdon-Down's syndrome; Mental retardation
Mongoloid palpebral fissure in trisomy 22, 882
Mongoloid stigmata, 881
Monoiodoacetate and carbohydrate metabolism, 914
Monosomy, 789
  partial, 792
  partial 21–22, 884
  monosomy 16, 882
Morphogenesis, 786
Mosaicism, 789, 888
  in indeterminate polysomy, 885
  in Langdon-Down's syndrome, 882
  mosaicism D, 868
  mosaicism E, 879
  and trisomy D1, 808
Mouth
  anomalies of, 831
    in trisomy E, 872
Musculoskeletal anomalies in trisomy E, 869–870
Mutation, 783
Myelinization, retarded, 929–930
Myopia
  high, bilateral in trisomy 22, 882
    in trisomy E, 869
  with optic atrophy, 865
  retinal detachment in, 966–970

Neck, short, in trisomy E, 872
Neuritis
  bilateral, developing into optic atrophy, 1003
  optic, and Leber's disease, 1016, 1027
  retrobulbar. *See* Leber's disease
Neurofibromatosis and coloboma of iris, 801
Niemann-Pick disease, 915
Nose, malformations of, 821, 830, 832
Nystagmus
  and optic atrophy; dominant, 1006
    recessive, 999
  pendular, in Leber's disease, 932
  penetrance of gene in, 784

Oligophrenia. *See* Imbecility; Mental retardation
Opacities
  corneal, in trisomy D1, 859
  lens, 866
    in trisomy E, 869
    types in Langdon-Down's syndrome, 881
Opsin, normal, 912
Optic atrophy. *See* Atrophy, optic
Optic cleft, closure of, 797
Optic disc
  coloboma of, bilateral, 869
    in mosaicism E, 879
    in trisomy E, 875
Optic nerve
  aplasia of, 859
  coloboma of, 801–802, 859
    and trisomy E, 809
  congenital affections of, 929–931
  hypoplasia of, 859
  See also Atrophy, optic, hereditary
Orbital cysts and coloboma of iris, 801
Organizers, 786
Oxalosis, 922–923

Palate, arched, 825, 831
Palpebral fissures
  antimongoloid slant of, 885
  narrowing of, in Marfan's syndrome, 887
Papilledema in Leber's disease, 1017–1018
Parents, consanguineous, 803, 804, 805, 915
  in cryptophthalmia, 819
  and idiopathic retinoschisis, 979, 981
  in Leber's disease, 943, 1029
  and malformations of genitals, 832
  and recessive optic atrophy, 999–1000, 1001, 1002
  and retinal detachment, 969
  and risk of recessive ocular disease, 778
  and trisomy E, 871
Patau's syndrome. *See* Trisomy D1
Penetrance, 781, 782, 783–784
Philadelphia chromosome. *See under* Chromosome
Photophobia, 922
Photoreceptors, development of, 911, 912
Physicochemical nature of gene action, 784
Pigmentation, retinal, absence in Leber's disease, 932, 933
Pigment epithelium
  atrophy of, 949
  depigmentation in Leber's disease, 946
Pleiotropic action of gene, 783
Polydactyly, 862
  in Marfan's syndrome, 887
  in trisomy D1, 851
  in trisomy E, 869
Polyneuritiformis heredopathia atactica hemeralopica. *See* Refsum's syndrome
Polyploidy, 886
Polysomy, 789
  indeterminate, case histories, 885

Primary vitreous, persistence of, 853
Protein metabolism, disorders of, 912, 920–921
Pseudoachondroplasia, in deletion G, 884
Pseudodominance. *See under* Dominance
Pseudoglaucoma, 1013
Pseudogliomata, 930–931
Pseudohermaphroditism, 821
Pseudomongolism. *See* Langdon-Down's syndrome
Pseudoretinopathy, 938–940
  syphilitic, 938
  viral, 914
Pseudorosettes
  in retinal tissue, 860
    in trisomy D1, 855, 856
Psychic disturbances, in Leber's disease, 1019–1020
Psychomotor retardation
  in deletion E, 878
  in Hooft's syndrome, 917
  in orodigitofacial syndrome, 839
Ptosis in trisomy E, 869
Pulmonary anomalies in trisomy E, 870
Pupillary membrane, persistence of, in partial monosomy 21–22, 884
Pyloric stenosis in partial monosomy 21–22, 884

Reese's retinal dysplasia, 808, 930, 931
Refsum's syndrome, 915–916
Renal aplasia, 822
Renal malformations in trisomy D1, 863
Retardation. *See* Mental retardation; Psychomotor retardation
Retina
  lesions in Leber's disease, 944, 945
    four groups of, 932–936
  reaction to iodoacetate, 913
Retinal degeneration in trisomy 22, 882
Retinal detachment
  etiology of, 965
  hereditary, 965–974
    and myopia, 967–968
    myopic and nonmyopic, 971–974
  and idiopathic retinoschisis, 982
  and macrofibrillar vitreoretinal degeneration, 987, 988, 989, 990
  modes of transmission, 991–992
  in Wagner's hyaloidoretinal degeneration, 986
Retinitis pigmentosa, classic features of, 934–936
Retinoblastoma, deletion D in, 868
Retinopathy
  pigmental; in choroideremia, 949, 950
    in Leber's disease, 935
  rubellar; and Leber's disease, 937–938, 939
  salt-and-pepper type, 933
  secondary to virus infection, 940
Retinoschisis, 973
  idiopathic; complicated by retinal detachment, 976, 981–982
    with early hemeralopia, 980–983
    in young subjects, 974–975, 979, 980
Rhodopsin, formation of, 912
Rocker-bottom foot, 962
  in deletion E, 879
  in trisomy E, 870

Satellites, giant, 793, 886–887
Schlemm, canal of, 854
Sclerosis
  of choriocapillaris, in Leber's disease, 944
  choroidal. *See* Choroidal sclerosis
Scotoma, 1018
Skin changes in Leber's disease, 942
Skin rash in Hooft's syndrome, 916
Skull
  anomalies of, 832
  radiography of, in cryptophthalmia, 829

Sodium bromacetate, 914
Sodium monoiodoacetate, 913
Specificity, 784
Sphingolipidoses, 915
Spina bifida in trisomy D1, 864
Sternum, malformations of, in Marfan's syndrome, 887
Stillborn, and cryptophthalmia, 820
Strabismus
  convergent; in Langdon-Down's syndrome, 881
  divergent, in deletion E, 876
  in double trisomy D, 864
  in indeterminate polysomy, 885
  in partial trisomy D1, 865
Sturge-Weber angiomatosis, trisomy 22 in, 882, 883
Symblepharon, congenital, 826, 827
Syndactyly, 821, 825, 826, 830, 832, 862
  in Marfan's syndrome, 887
  in trisomy E, 869, 875
Syndrome of the first arch, 800

Tapetoretinal degeneration
  in animals, spontaneous and experimental, 911–914
  in Hooft's syndrome, 916
  and lipidoses, 915
Tapetoretinal heredodegeneration, Leber's congenital. *See* Leber's disease
Teeth
  crowded, in deletion E, 876
  faulty implantation of, 825
Testis, reaction to iodoacetate, 914
Tetrasomy, 789
Thorax, anomalies of, in trisomy E, 872
Thrombocytopenia, secondary, in trisomy 22, 884
Thumb
  high implantation of, in deletion E, 876
  malformation of, in trisomy E, 869
  retroflexion of, 862
Thyroid metabolism, disorders of, 888
Tissue cultures, 888
Tissue differentiation, 786
Translocation of chromosomes, 791–792
  balanced, 791, 888
  familial, 864
  not balanced, 791
  translocation A, 840–842
  translocation D/D, 865, 867
  translocation D/E, 865
  translocation D/F, 867
  translocation D/G, 865
  translocation D/4–5, 866
  translocation E, 878
  translocation 4/5, 845–846
Transvitamin A, 912, 913
Trisomies, 789
  partial, 792
    lethal effect in males, 840
  trisomy A, 839–840
  trisomy B, partial, 844–845
  trisomy C, 848–849
    partial, 849
  trisomy D, double, 864
    and Reese's retinal dysplasia, 931
  trisomy D1, 807–808, 850–864
    anomalies other than ocular, 862–864
    ocular signs in, 858–862
    partial, 864–867
      and translocation D/D, 867
  trisomy E, 808–809, 868–873
    double, 874
    partial, 874
  trisomy 18. *See* Mosaicism E; Trisomies, trisomy E
  trisomy F (19–20), 879–880
  trisomy G, 809, 882
  trisomy 13. *See* Trisomy D1
  trisomy 21, 790, 880–882
    with trisomy D1, 864
  trisomy 22, 882–884
Tryptophan metabolism, disturbance of. *See* Hooft's hypolipidemic syndrome

Twins
isogenic, 786–787
monozygotic, 773–774, 786–787
coloboma of iris in, 800
complicated microphthalmia in, 804
and Leber's disease, 1021
optic atrophy in, 1006
unilateral detachment in, 967
uniovular. *See* Twins, monozygotic

Urinary tract, in trisomy E, 873
Uvea
coloboma of, 800, 807, 852, 853, 854, 861, 865
and indeterminate polysomy, 885
in mosaicism E, 879
in trisomy, E, 869

Van Gogh's xenon stroboscope, 827
Vertebral anomalies in Marfan's syndrome, 887
Viral infection in Leber's disease, 1032
Virus, effect on retinal metabolism, 914
Visceral anomalies in trisomy D1, 863–864
Vision, central, in optic atrophy, 1004
Visual acuity in Leber's disease, 1018
Visual functions in male choroideremia, 949–950
Visual purple, disturbance in formation of, 912
Visual recuperation in Leber's disease, 1018
Vitamin A aldehyde, 912
Vitreoretinal degeneration, hereditary, 974–991
dominant, 983–991
macrofibrillar (Favre), 987-991
recessive, 980-983
autosomal, of Goldmann-Favre, 981
sex-linked, 974–980
symptomatology, 974–976
sex-linked; genetics of, 976–980
Vitreous, primary, persistence of, 930
Vitreous veils, 975–976

Women
affected by Leber's disease, 1032
See also Carriers, females as; Heterozygous women; Homozygous women
Wrist, deviation of, in trisomy E, 869

Yellowish spots in Leber's disease, 935